Simple Summary Immunotherapy has considerably changed the outcomes of cancer patients. However, only a minority of patients respond to immunotherapy and may suffer toxicity. Moreover, strong predictive and prognostic markers… Click to show full abstract
Simple Summary Immunotherapy has considerably changed the outcomes of cancer patients. However, only a minority of patients respond to immunotherapy and may suffer toxicity. Moreover, strong predictive and prognostic markers are lacking. The number of overweight and obese individuals is steadily increasing in developed countries. This factor is easy to measure and leads to a chronic inflammatory state. We therefore evaluated the relationships between body mass index, survival, and immune-related adverse events in patients treated by immunotherapy for metastatic cancer. Overall survival was better in patients with a BMI ≥ 25 and in those experiencing toxicity. More than 60% of obese patients experienced toxicity. These results should raise the awareness of physicians concerning the importance of body composition in the management of patients on immunotherapy. Body composition, including lean and fat tissue proportions, could be analyzed by CT scans in this selected population. Abstract The response to immunotherapy has been little investigated in overweight and obese cancer patients. We evaluated the relationships between BMI, toxicity, and survival in patients treated by immunotherapy for metastatic cancer. We included metastatic cancer patients treated by immunotherapy between January 2017 and June 2020 at the Centre Léon Bérard. In total, 272 patients were included: 64% men and 36% women, with a median age of 61.4 years. BMI ≥ 25 in 34.2% and 50% had non-small cell lung cancer (n = 136). Most received monotherapy, with nivolumab in 41.9% and pembrolizumab in 37.9%. Toxicity, mostly dysthyroiditis, occurred in 41%. Median overall survival (OS), estimated by Kaplan–Meier analysis, was significantly longer for patients with a BMI ≥ 25 than for those with a BMI < 25 (24.8 versus 13.7 months HR = 0.63; 95% CI 0.44–0.92, p = 0.015), and for patients experiencing toxicity than for those without toxicity (NR versus 7.8 months, HR = 0.22; 95% CI 0.15–0.33, p < 0.001). Adjusted OS was associated with toxicity, and the occurrence of toxicity was associated with sex and histological features but not with BMI. Thus, being overweight and experiencing toxicity was associated with longer overall survival in patients treated by immunotherapy. More attention should be paid to body composition in the care of cancer patients.
               
Click one of the above tabs to view related content.